Cardio3 BioSciences
MONT-SAINT-GUIBERT, Belgium, November 17, 2010 - The Belgian biotechnology company, Cardio3 BioSciences - a
leader in discovery and development of regenerative and protective therapies
for the treatment of cardiovascular diseases - today announces positive
six-month results, including significant functional and clinical benefit,
from the Phase II clinical trial of its development programme C-Cure(R),
designed as a novel stem cell therapy for heart failure based on breakthrough
technology.
MONT-SAINT-GUIBERT, Belgium, August 16, 2010 - Cardio3 BioSciences, a leading Belgian biotechnology company specialising
in regenerative therapies for the treatment of cardiovascular disease, today
announces that the key scientific work underlying its lead pharmaceutical
product C-Cure(R), a revolutionary stem cell treatment for heart failure, has
been published in the Journal of the American College of Cardiology (JACC).
MONT-SAINT-GUIBERT, Belgium, July 29, 2010 - Cardio3 BioSciences, a leading Belgian biotechnology company specialising
in regenerative therapies for the treatment of cardiovascular diseases, today
announces that Atta Behfar, M.D.
MONT-SAINT-GUIBERT, Belgium, July 14, 2010 - Cardio3 BioSciences, a leading Belgian biotechnology company specialising
in regenerative therapies for the treatment of cardiovascular diseases, today
announces that Dr.
MONT-SAINT-GUIBERT, Belgium, June 29, 2010 - Cardio3 BioSciences, a leading Belgian biotechnology company specialising
in regenerative therapies for the treatment of cardiovascular diseases, today
announces positive safety data and preliminary efficacy results from its
clinical trial of C-Cure(R), a breakthrough stem cell therapy for heart
failure.
More News
- Cardio3 BioSciences Announces Promising Pre-Clinical Data for Proprietary C-Cath(R) Catheter
- 45 Patients Enrolled in Study Designed to Evaluate the Ability of Cardiopoietic Cells to Restore Cardiac Function
- Clinical Center of Serbia, Institute for Cardiovascular Diseases Treats First Patient in Trial of Pioneering Stem Cell-Derived Therapy for Heart Failure
- Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
